Condition: Developmental and Epileptic Encephalopathy 1 · Sponsor: Praxis Precision Medicines
A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension
This description comes directly from the study's public registry record.
Head of Pharmacovigilance · 617-300-8460 · clinicaltrials@praxismedicines.com
Always discuss trial participation with your own doctor first.
| Praxis Research Site | La Jolla, California, United States | Recruiting |
| Praxis Research Site | Gulf Breeze, Florida, United States | Recruiting |
| Praxis Research Site | Chevy Chase, Maryland, United States | Recruiting |
| Praxis Research Site | Roseville, Minnesota, United States | Recruiting |
| Praxis Research Site | Hackensack, New Jersey, United States | Recruiting |
| Praxis Research Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Praxis Research Site | Heidelberg, Victoria, Australia | Recruiting |
| Praxis Research Site | Rio Grande, Do Sul, Brazil | Recruiting |
| Praxis Research Site | Paraná, Brazil | Recruiting |
| Praxis Research Site | Rio de Janeiro, Brazil | Recruiting |
| Praxis Research Site | São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07010471